1. A pharmaceutical combination comprising (a) an Hsp90 inhibitor compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof, wherein R is selected from the group consisting of: (1) hydrogen, (2) halogen, (3) hydroxyl, (4) ( C-C) alkoxy group, (5) thiol, (6) (C-C) alkithiol, (7) substituted or unsubstituted (C-C) alkyl, (8) substituted or unsubstituted amino group, (9) substituted or unsubstituted aryl, (10) substituted or unsubstituted heteroaryl, and (11) substituted or unsubstituted heterocyclyl； R is selected from the group consisting of: (1) hydrogen, (2) substituted or unsubstituted (C-C) alkyl, (3) substitution hemp or unsubstituted (C-C) alkenyl, (4) substituted or unsubstituted (C-C) alkynyl, (5) substituted or unsubstituted (C-C) cycloalkyl, (6) substituted or unsubstituted (C-C) cycloalkenyl, ( 7) substituted or unsubstituted aryl, (8) substituted or unsubstituted heteroaryl, and (9) substituted or unsubstituted heterocyclyl； R is selected from the group consisting of: (1) substituted or unsubstituted (C-C) cycloalkyl, (2) substituted or unsubstituted ( C-C) cycloalkenyl, (3) substituted or unsubstituted aryl, (4) substituted or unsubstituted heteroaryl, and (5) substituted or unsubstituted heterocycle lil； provided that if R is an amino group, then R is not phenyl, 4-alkylphenyl, 4-alkoxyphenyl or 4-halogenophenyl； or a compound of formula (E) wherein R is selected from the group consisting of methylaminocarbonyl CHCHNHC (= O) -, ethylaminocarbonyl CHCHNHC ( = O) -, propylaminocarbonyl CHCHCHNHC (= O) - or isopropylaminocarbonyl (CH) CHNHC (= O) -)； R is selected from the group consisting of methyl, ethyl, isopropyl, bromine or chlorine； and R is —CHNRR or —NRR, where the substituted amino group —NRR is morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, ethylamine, isopropylamine, diethylamine, c�1. Фармацевтическая комбинация, содержащая(а) соединение-ингибитор Hsp90 формулы (I)или его фармацевтически приемлемую соль или пролекар
